Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Colorectal Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Colorectal Cancer
    TopAbstracts in Colorectal Cancer 08/06/2008 - (DGNews)
    FDA Clears the Pathwork Tissue of Origin Test - (DGNews)
    TopAbstracts in Colorectal Cancer 07/23/2008 - (DGNews)
    Cetuximab as First-Line Treatment in Metastatic Colorectal Cancer Approved in Europe - (DGNews)
    Cetuximab Approved in Japan for Treatment of Metastatic Colorectal Cancer - (DGNews)

    News archive

     Recent webcasts/CME - Colorectal Cancer
    • Treatment of Advanced Colorectal Cancer: What Are the Clinical Implications of Latest Data?
    • Update on Targeted Therapies in mCRC: How to Choose to Maximize Efficacy and Minimize Toxicity
    • Interpreting Current Evidence in mCRC: Progress Towards Individualized Therapy
    • Background: Antiangiogenic Therapy in Lung and Colorectal Cancer: Patient Scenarios for Everyday Practice
    • Colorectal Cancer Screening and Prevention

      Webcasts/CME archive

       Recent cases - Colorectal Cancer
        Early Distant Relapse after Optimal Local Control in Locally Advanced Rectal Cancer
        Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease) in a Patient Receiving Bevacizumab for Metastatic Colorectal Cancer: A Case Report
        Granulocyte-Colony Stimulating Factor Producing Rectal Cancer
        Burkitt's Lymphoma of the Colon and Bronchi: Three Case Reports
        Colonoscopy is Mandatory After Streptococcus Bovis Endocarditis: A Lesson Still Not Learned. Case Report

        Cases archive
          




        my personal edition > colorectal cancer > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Capecitabine Shows Improved Safety Over 5-fluorouracil-based Adjuvant Treatment for Colon Cancer

        A DGReview of :"Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial"
        Annals of Oncology

        12/04/2003
        By Mary Beth Nierengarten


        For patients with metastatic colorectal cancer, oral capecitabine may be a more attractive first-line therapy over the current choice of 5-fluorouracil-leucovorin (5-FU/LV) based on its improved safety profile, reports a multinational study.

        Although adjuvant 5-FU/LV has improved outcomes for patients with Dukes' C colon (stage III) colon cancer and is considered standard treatment, it is often not used in community practice because of associated adverse effects and subsequent poor compliance. Along with a high activity profile, capecitabine has been shown to be well tolerated and convenient or patients with metastatic disease.

        To compare the efficacy and safety of capecitabine and 5-FU/LV for patients with Dukes' C colon cancer, W. Scheithauer, MD, Vienna University Medical School, Austria, and colleagues randomised 993 patients to 24 weeks of oral capecitabine (1250 mg/m2), twice daily, days 1-14 every 21 days) and 974 patients to intravenous bolus 5-FU (425 mg/m2) with intravenous leucovorin (20 mg/m2), days 1-5, repeated every 28 days. For patients with moderate renal impairment, the starting dose of capecitabine was eventually reduced by 25%. The purpose of this study was to report the prospective results of a planned safety analysis at 19 months after study enrolment.

        Overall, patients receiving capecitabine experienced significantly less adverse events than those receiving 5-FU-LV, with less diarrhoea (46% vs. 64%), nausea/vomiting (36% vs. 51%), alopecia (6% vs. 22%), stomatitis (22% vs. 60%), and neutropenia (2% vs. 8%) (significance of P < .001 for all comparisons). Severe adverse events were also significantly reduced with capecitabine, including less grade 3 or 4 stomatitis (2% vs. 14%), grade 3 or 4 neutropenia (0.6% vs. 5%), and febrile neutropenia/sepsis (0.3% vs. 3%) (significance of P < .001 for all comparisons). Hand-foot syndrome was the only significantly increased adverse event associated with capecitabine (62% vs. 10%; P < .001).

        Tolerability of capecitabine was not dependent on age, with comparable early severe toxicities reported in patients 65 years or older or those younger than 65 (4.9% vs. 6.3%, respectively). In contrast, patients over 65 years old who were receiving 5-FU-LV reported higher incidence of early severe toxicities compared to younger patients (20% vs. 15%, respectively).

        Although the efficacy results of this trial will not expected until next year, the authors conclude that "from a safety perspective, capecitabine can replace 5-FU-LV as the standard adjuvant treatment for patients with colon cancer."

        Annals of Oncology 2003;14:1735-1743. "Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send